期刊文献+

氨氯地平联合替米沙坦治疗对老年轻、中度高血压病患者左心室结构和功能的影响 被引量:3

The treatment effects of amlodipine combined with telmisartan in elderly mild to moderate hypertensive patients complicated by left ventricular hypertrophy
暂未订购
导出
摘要 目的:探讨氨氯地平联合替米沙坦治疗对老年轻中度高血压病患者左心室结构和功能的影响。方法:选择50例老年原发性轻中度高血压病伴左心室肥厚患者,给予氨氯地平(2.5 mg)联合替米沙坦(40 mg)治疗24个月,治疗前及治疗后24月分别进行血压测量及超声心动图检查,对参数(左室舒张末期内径、左室后壁舒张末期厚度、室间隔舒张末期厚度、左室心肌重量指数、左室射血分数及E/A)进行对比及统计学分析。结果:治疗24个月末氨氯地平联合替米沙坦治疗高血压病的降压总有效率为96.0%,左室舒张末期内径、室间隔厚度、左室后壁舒张末期厚度、左室心肌重量指数均较治疗前明显下降,左室射血分数及E/A均较治疗前显著提高(P<0.01)。结论:氨氯地平联合替米沙坦治疗高血压病伴左心室肥厚患者,能改善左心室收缩舒张功能,逆转左心室肥厚,有效控制高血压病患者的左室重构。 Objective:To evaluate the treatment effects of amlodipine combined with telmisartan in elderly mild to moderate hypertensive patients complicated by left ventricular hypertrophy(LVH).Methods 50 elderly mild to moderate hypertensive patients with LVH were treated by amlodipine combined with telmisartan.After 24 months blood pressure、left ventricular end diastolic dimension(LVDd)、thickness of interven tricular septum(IVSTd)、left ventricular posterior wall end diastole(LVPWTd)、left ventricular mass indexes(LVMI)、ejection fraction of left ventricle(EF)and E/A were contrasted and analyzed.Results:After 24-month treatment,blood pressure control rate reached 96.0,LVDd、IVSTd、LVPWTd and LVMI lowered more significantly,EF and E/A increased more significantly compared with pretreatment(P0.01).Conclusion:The treatment of amlodipine combined with telmisartan in elderly mild to moderate hypertensive patients complicated by LVH can improve left ventricular diastolic function and reverse enlarged left ventricle
出处 《南通大学学报(医学版)》 2011年第6期467-468,471,共3页 Journal of Nantong University(Medical sciences)
关键词 高血压病 左心室肥厚 氨氯地平 替米沙坦 hypertension left ventricular hypertrophy amlodipine telmisartan
  • 相关文献

参考文献8

二级参考文献71

  • 1李华,初少莉,孔燕,张博恒,吴顺娣,张瑾,朱鼎良.比索洛尔/氢氯噻嗪复方片治疗轻中度原发性高血压[J].中华高血压杂志,2007,15(2):141-145. 被引量:8
  • 2戴瑞鸣 林果为.内科学新理论与新技术[M].上海:上海科技教育出版社,1995.21.
  • 3-.-[J].高血压杂志,1998,16(1):1-1.
  • 4Lorell BH,Carabello BA.Left ventricular hypertrophy:pathogenesis,detection,and prognosis.Circulation,2000,102:470-479.
  • 5Wollert KC,Drexler H.Regulation of cardiac remodeling by nitric oxide:focus on cardiac myocite hypertrophy and apaptosis.Heart Fail Rev,2002,7:317-325.
  • 6Kempf T,Wollert KC.Nitric oxide and the enigma of cardiac hypertrophy.Bioessays,2004,6:608-615.
  • 7Russell B,Motlagh D,Ashley WW.Form follows function:how muscle shape is regulated by work.J Appl Physiol,2000,88:1127-1132.
  • 8Ozaki M,Kawashirna S,Yamashita T,Hirase T,Ohashi Y,Inone N,et al.Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion.Circ J,2002,66:851-856.
  • 9Von Harsdorf R,Kang RE,Fullerton M,Woodcock EA.Myocardial stretch stimulates phoephatidyl-inositol turnover.Circ Res,1989,65:494-501.
  • 10Sussman A,Mcculloch A,Borg TK.Dance band on the titanic:biomechanical signaling in cardiac hypertrophy.Cire Res,2002,91:888-898.

共引文献67

同被引文献26

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部